Trial Profile
A randomized phase II study of systemic chemotherapy with and without trastuzumab followed by surgery in HER2 positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis (JCOG1301:Trigger Study)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Cisplatin; Gimeracil/oteracil/tegafur
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms TRIGGER
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 27 Nov 2015 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network - Japan record.